Your browser doesn't support javascript.
loading
Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site.
Stadlbauer, Daniel; McMahon, Meagan; Turner, Hannah L; Zhu, Xueyong; Wan, Hongquan; Carreño, Juan Manuel; O'Dell, George; Strohmeier, Shirin; Khalil, Zain; Luksza, Marta; van Bakel, Harm; Simon, Viviana; Ellebedy, Ali H; Wilson, Ian A; Ward, Andrew B; Krammer, Florian.
Affiliation
  • Stadlbauer D; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • McMahon M; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Turner HL; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Zhu X; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Wan H; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
  • Carreño JM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • O'Dell G; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Strohmeier S; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Khalil Z; Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Luksza M; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • van Bakel H; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Simon V; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ellebedy AH; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Wilson IA; Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ward AB; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Krammer F; Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nat Commun ; 13(1): 7864, 2022 12 21.
Article in En | MEDLINE | ID: mdl-36543789
ABSTRACT
Contemporary influenza A H3N2 viruses circulating since 2016 have acquired a glycosylation site in the neuraminidase in close proximity to the enzymatic active site. Here, we investigate if this S245N glycosylation site, as a result of antigenic evolution, can impact binding and function of human monoclonal antibodies that target the conserved active site. While we find that a reduction in the inhibitory ability of neuraminidase active site binders is measurable, this class of broadly reactive monoclonal antibodies maintains protective efficacy in vivo.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza A Virus, H3N2 Subtype / Antibodies, Monoclonal / Neuraminidase Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza A Virus, H3N2 Subtype / Antibodies, Monoclonal / Neuraminidase Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2022 Type: Article Affiliation country: United States